Penicillins

Bacteria survive because they are wrapped in a rigid mesh called the cell wall, built from a cross-linked polymer, peptidoglycan. That wall is what holds the cell together against its own high internal osmotic pressure — without it, water rushes in and the cell bursts. Crucially, human cells have no cell wall, so a drug that attacks wall-building harms the bacterium and largely spares us. That is the elegance of the β-lactams and the reason they are usually so well tolerated.

A penicillin is a β-lactam — named for a four-membered ring at its core. It works by binding enzymes called penicillin-binding proteins (PBPs), the "bricklayers" that perform the final cross-linking (transpeptidation) step of peptidoglycan assembly. Block the bricklayers and the wall can’t be finished; the weakened cell lyses and dies. Because it kills rather than merely stalls the bacterium, a penicillin is bactericidal — but only against actively dividing organisms (a wall under construction is the vulnerable target).

Bacteria fight back by making β-lactamase (penicillinase) — an enzyme that snips the β-lactam ring open before it can reach the PBPs. The whole family tree of penicillins is really the story of widening coverage and countering that enzyme. Natural penicillins (penicillin G, penicillin V) hit mostly gram-positives and remain the drug of choice for syphilis and strep throat. Aminopenicillins (amoxicillin, ampicillin) reach more gram-negatives. Penicillinase-resistant agents (nafcillin, oxacillin, dicloxacillin) are built to survive staph β-lactamase. Extended-spectrum piperacillin even covers *Pseudomonas*.

The cleverest countermove is to pair a penicillin with a β-lactamase inhibitor — clavulanate, sulbactam, or tazobactam. These have little antibacterial power of their own; instead they act as decoys that soak up and disable the β-lactamase, protecting the partner penicillin so it can reach its target. That is what amoxicillin-clavulanate (Augmentin), ampicillin-sulbactam (Unasyn), and piperacillin-tazobactam (Zosyn) are — a penicillin plus its bodyguard.

The signature risk of penicillins isn’t organ toxicity — it’s hypersensitivity, and it defines the nurse’s role. The β-lactam can attach to the patient’s own proteins and become a target for the immune system, so reactions span a spectrum from a mild maculopapular rash all the way to IgE-mediated anaphylaxis — hives, angioedema, bronchospasm, and circulatory collapse, usually within minutes. This is why a thorough allergy history precedes the first dose and why patients are observed for ~30 minutes after a parenteral dose with epinephrine at hand. (A useful nuance: the classic amoxicillin rash during mono/EBV is a benign virus-drug interaction, *not* a true penicillin allergy — don’t mislabel it.)

Two facts modernize the allergy conversation. First, roughly 10% of people report a penicillin allergy, but fewer than 1% are truly allergic — most can be safely "de-labeled," which matters because unnecessary avoidance pushes patients toward broader, riskier antibiotics. Second, the old teaching that penicillin-allergic patients have a ~10% cross-reaction with cephalosporins is overstated; the real risk is driven by similar side chains, and is under ~1% for cephalosporins with dissimilar side chains — only a prior *severe/anaphylactic* penicillin reaction is a firm reason to avoid them. Beyond allergy, watch for C. difficile diarrhea (flora disruption), and — at very high doses in renal impairment — seizures (the renally cleared drug accumulates and antagonizes GABA).